1. What Biopharma Intelligence Actually Does (and What Most Firms Think It Does) 1.1 The Operational Definition Biopharmaceutical business intelligence […]
1. Executive Summary Between now and 2032, an estimated 110 biological medicines in Europe will lose intellectual property protection, with
Generic drug development past the ANDA filing date is where most companies either build durable competitive moats or bleed out
Post-ANDA Patent Strategy: The Complete Playbook for Generic Market Domination Read Post »
Introduction: Generic Drugs as the Core Economic Infrastructure of Global Healthcare Scale, Dominance, and the Savings Calculus Generic drugs now
The Global Generic Drug Market: Trends, Opportunities, and Challenges Read Post »
1. Executive Summary and Scope Generic drugs fill 91% of all U.S. prescriptions and generated an estimated $2.44 trillion in
1. Why Cost Structure Is Your Only Durable Weapon The global generic drug market reached approximately $491 billion in 2024.
Section 1: The Affordability Paradox: Why the Generic Market Rewards Complexity, Not Cost The generic drug industry has an identity
Generic Drug Market Strategy: The Complete Competitive Playbook Read Post »
1. The CDMO Market: Size, Consolidation, and the IP Stakes That Changed Everything The global contract development and manufacturing organization
A technical deep dive for IP teams, portfolio managers, R&D leads, and institutional investors in biologics and biosimilar development. Why
Biosimilar Regulatory Strategy: The Complete Playbook for FDA, EMA, and Global Approval Read Post »
Get fresh news and insights, drug patent expirations & more…
